Enfusion

Enfusion Forward P/E

Delisted

The Forward P/E Ratio of Enfusion (ENFN) as of Nov 7, 2026 is 494.92. In the previous year, Forward P/E Ratio was 231.89 — a change of 113.43% (higher).

Forward P/E

494.92

YoY

113.43%

Last updated:

Forward P/E Ratio of Enfusion is 2024 494.92 . Forward P/E Ratio of Enfusion was 2023 231.89 . It decreases by 113.43% higher compared to the previous year.

The Enfusion Forward P/E history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Forward P/E
Date
Forward P/E
Jan 1, 2019
110.40 USD
Jan 1, 2020
344.04 USD
Jan 1, 2021
-4.95 USD
Jan 1, 2022
-105.34 USD
Jan 1, 2023
231.89 USD
Jan 1, 2024
494.92 USD
The Enfusion Forward P/E history
YEARForward P/EYoY
494.92+113.43%
231.89-320.13%
-105.34+2,028.04%
-4.95-101.44%
344.04+211.65%
110.40—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Enfusion Stock analysis

What does Enfusion do? Enfusion Inc. generates revenue through cloud-native multi-tenant software solutions tailored for alternative and institutional investment managers. Its core products include the Portfolio Management System (PMS), Order and Execution Management System (OEMS), Accounting/General Ledger System, and Enfusion Analytics System, which collectively enable real-time investment decision-making. The company serves investment managers who require integrated systems for the full investment lifecycle, with PMS constructing and rebalancing portfolios while generating a real-time investment book of record, and OEMS facilitating electronic trade order communication for portfolio managers, traders, compliance teams, and analysts. The company's solution integrates technology-powered managed services to drive insights and control over investment operations. Enfusion's end-to-end functionality supports the entire investment process, from portfolio construction to trade execution, with PMS and OEMS operating in tandem to provide a seamless workflow. Investment managers across alternative and institutional segments purchase these integrated systems to enhance operational efficiency and decision-making capabilities. Enfusion's software is designed to serve the full investment lifecycle, with its systems integrated to provide a unified platform for portfolio management, order execution, accounting, and analytics. The company's revenue model is based on delivering these comprehensive solutions to investment managers who rely on real-time data and integrated workflows to manage their operations effectively. Enfusion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Enfusion stock

Forward P/E Ratio of Enfusion is 494.92 in 2024.

Forward P/E Ratio of Enfusion changed from 231.89 to 494.92, representing a 113.43% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Forward P/E Ratio Enfusion since 2006 – with annual values, charts, and detailed analysis.

The Forward P/E uses estimated future earnings to value a stock. A lower forward P/E relative to the trailing P/E suggests analysts expect earnings growth.

To evaluate Forward P/E Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Forward P/E Ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Forward P/E Ratio's Enfusion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — Enfusion

All Key Metrics — Enfusion